Only in Titles

           Search results for: Antibody   

paperclip

#   // Save this To Up


1212 related Products with:

No related Items

Related Pathways

  •  
  • No related Items
paperclip

#31968262   // Save this To Up

Memory B Cell Activation, Broad Anti-influenza Antibodies, and Bystander Activation Revealed by Single-Cell Transcriptomics.

Antibody memory protects humans from many diseases. Protective antibody memory responses require activation of transcriptional programs, cell proliferation, and production of antigen-specific antibodies, but how these aspects of the response are coordinated is poorly understood. We profile the molecular and cellular features of the antibody response to influenza vaccination by integrating single-cell transcriptomics, longitudinal antibody repertoire sequencing, and antibody binding measurements. Single-cell transcriptional profiling reveals a program of memory B cell activation characterized by CD11c and T-bet expression associated with clonal expansion and differentiation toward effector function. Vaccination elicits an antibody clone, which rapidly acquired broad high-affinity hemagglutinin binding during affinity maturation. Unexpectedly, many antibody clones elicited by vaccination do not bind vaccine, demonstrating non-specific activation of bystander antibodies by influenza vaccination. These results offer insight into how molecular recognition, transcriptional programs, and clonal proliferation are coordinated in the human B cell repertoire during memory recall.

1560 related Products with: Memory B Cell Activation, Broad Anti-influenza Antibodies, and Bystander Activation Revealed by Single-Cell Transcriptomics.

Mouse Anti-Human CD18 (Ac Rabbit Anti-Human B-cell Rabbit Anti-Human Red Blo Anti bodywall muscle cell Mouse Anti-Human Prolifer Mouse Anti-Human Endothel Anti-bodywall muscle cell Rat monoclonal anti mouse Rabbit Anti-Rat Androgen Rabbit Anti-Cell death in Rabbit Anti-cellulase Pol Anti BTG1(B cell transloc

Related Pathways

paperclip

#31968223   // Save this To Up

Lack of association between amino acid sequences of the bovine leukemia virus envelope and varying stages of infection in dairy cattle.

We collected 724 blood samples from dairy cattle from six Mexican states, and tested them for the presence of antibodies against BLV using a commercial ELISA test. Our study groups consisted of 32 samples: 12 asymptomatic cows, 12 cows with lymphocytosis and 8 samples of tumor tissue of the abomasum and heart of cattle with lymphoma. We designed three pairs of primers to amplify the complete BLV env gene, and obtained a fragment of 1548 nucleotides in length with the sequenced products. According to the phylogenetic tree we constructed to identify the viral genotype, 96.87% of the sequences grouped into genotype 1, while a single sample from a cow with lymphocytosis (3.13%) was associated with genotype 3 sequences. The similarity between the Mexican BLV sequences ranged from 0.985 to 1.00. In addition, the proportion of non-synonymous and synonymous mutations indicated negative selection. We did not identify any conserved residues in the viral protein sequences that could be related to BLV infection stage in cattle. Proviral quantification was performed using quantitative polymerase chain reaction, and we used Mood´s median test as statistical analysis. We found no significant association between proviral load and phase of infection. The sequences showed high similarity without any association between BLV surface glycoprotein and the different infection stages, nor differences in the proviral load. BLV genotype 1 was identified as prevalent in the studied samples, and for the first time in Mexico, we identified BLV genotype 3 in cattle.

1099 related Products with: Lack of association between amino acid sequences of the bovine leukemia virus envelope and varying stages of infection in dairy cattle.

Ofloxacin CAS Number [824 5 (2 Aminoethylamino) 1 n 3-Amino-1,4-dimethyl-5H-p (2S,4S)-4-Amino-1,2-pyrro 7-Aminoheptanoic Acid Met EDANS sodium salt [5 ((2 3 Amino 2 chlorobenzoic a 5-Amino-2-naphthalenesulf Indole 5 carboxylic acid N-[2-[4-(Aminosulfonyl)ph Sterile filtered fetal bo Native Parainfluenza Viru

Related Pathways

paperclip

#31968188   // Save this To Up

IRON DEFICIENCY, A RISK FACTOR FOR THYROID AUTOIMMUNITY DURING SECOND TRIMESTER OF PREGNANCY IN CHINA.

Previous studies have reported an association between iron deficiency (ID) and increased thyroid peroxidase antibody (TPO-ab) during early pregnancy. The objective of this study was to explore the relationship between ID and thyroid dysfunction, as well as thyroid autoantibodies, during the second trimester of pregnancy. A total of 1592 pregnant women (13-28 weeks gestation) were enrolled in this cross-sectional study. According to serum ferritin (SF) concentrations, they were divided into ID (SF <20 μg/L) or non-ID (SF ≥20 μg/L) groups. Logistic regression analysis was used to evaluate the association between ID and subclinical hypothyroidism (thyroid-stimulating hormone [TSH] >4.0 mIU/L and free thyroxine [FT4] within the reference range) and thyroid autoimmunity. The prevalence of ID was 23.43% (373/1592). Compared with the non-ID group, the ID group had lower FT4 levels (13.94 [8.91-29.82] vs 14.63 [8.22-47.24] pmol/L, p<0.001]) and higher TSH levels (1.85 [0.01-7.84] vs 1.69 [0.01-10.2] mIU/L, p<0.05). Logistic regression analysis confirmed ID as a risk factor for increased thyroglobulin antibody (TG-ab) (odds ratio 1.974; 95% confidence interval 1.065, 3.657; p<0.05), but not for subclinical hypothyroidism or increased TPO-ab. ID is associated with increased TG-ab during the second trimester of pregnancy.

2134 related Products with: IRON DEFICIENCY, A RISK FACTOR FOR THYROID AUTOIMMUNITY DURING SECOND TRIMESTER OF PREGNANCY IN CHINA.

Multiple lung carcinoma ( Anti-ADAMTS-13 (A Disinti Rat monoclonal anti mouse Mouse Anti-Insulin-Like G Thyroid cancer tissue arr Apoptosis Inducing Factor Hamster anti mouse Insuli Breast invasive ductal ca Rabbit Anti-Osteo-Inducti Apoptosis Inducing Factor Rat monoclonal anti mouse Thyroid cancer test tissu

Related Pathways

paperclip

#31968077   // Save this To Up

Recapitulation of posttransfusion purpura by cross-strain platelet immunization in mice.

Posttransfusion purpura (PTP) is an uncommon but life-threatening condition characterized by profound thrombocytopenia occurring ∼1 week after a blood transfusion. The hallmark of PTP is a potent immunoglobulin G antibody specific for a transfused platelet-specific alloantigen, usually located on glycoprotein IIb/IIIa (GPIIb/IIIa; αIIb/β3 integrin). It is widely thought that this alloantibody somehow causes the thrombocytopenia, despite absence from host platelets of the alloantigen for which it is specific. In studies described here, we found that cross-strain platelet immunization in mice commonly induces GPIIb/IIIa-specific alloantibodies combined with platelet-specific autoantibodies and varying degrees of thrombocytopenia, and we identified 1 strain combination (129S1Svlm/PWKPhJ) in which 95% of immunized mice made both types of antibody and developed severe thrombocytopenia. There was a strong inverse correlation between autoantibody strength and platelet decline (P < .0001) and plasma from mice that produced autoantibodies caused thrombocytopenia when transfused to syngeneic animals, arguing that autoantibodies were the cause of thrombocytopenia. The findings define a model in which a routine alloimmune response to platelets regularly transitions to an autoimmune reaction capable of causing severe thrombocytopenia and support the hypothesis that PTP is an autoimmune disorder.

1409 related Products with: Recapitulation of posttransfusion purpura by cross-strain platelet immunization in mice.

AccuPower GreenStar qPCR Goat Anti- SENP7 (interna Liver cancer tissue array Rabbit Anti-APIP Apaf1 In Indole-2-carboxylic acid CDK2 & SMAD3 Protein Prot High density Lung cancer Rat Interleukin-6 IL-6 b-AP15 Mechanisms: Protea Goat Anti-Human BNIP1, (i Cytokine (Human) Antibody Goat Anti-Human TPTE PTEN

Related Pathways

paperclip

#31967991   // Save this To Up

Design and assessment of TRAP-CSP fusion antigens as effective malaria vaccines.

The circumsporozoite protein (CSP) and thrombospondin-related adhesion protein (TRAP) are major targets for pre-erythrocytic malaria vaccine development. However, the CSP-based vaccine RTS,S provides only marginal protection, highlighting the need for innovative vaccine design and development. Here we design and characterize expression and folding of P. berghei (Pb) and P. falciparum (Pf) TRAP-CSP fusion proteins, and evaluate immunogenicity and sterilizing immunity in mice. TRAP N-terminal domains were fused to the CSP C-terminal αTSR domain with or without the CSP repeat region, expressed in mammalian cells, and evaluated with or without N-glycan shaving. Pb and Pf fusions were each expressed substantially better than the TRAP or CSP components alone; furthermore, the fusions but not the CSP component could be purified to homogeneity and were well folded and monomeric. As yields of TRAP and CSP fragments were insufficient, we immunized BALB/c mice with Pb TRAP-CSP fusions in AddaVax adjuvant and tested the effects of absence or presence of the CSP repeats and absence or presence of high mannose N-glycans on total antibody titer and protection from infection by mosquito bite both 2.5 months and 6 months after the last immunization. Fusions containing the repeats were completely protective against challenge and re-challenge, while those lacking repeats were significantly less effective. These results correlated with higher total antibody titers when repeats were present. Our results show that TRAP-CSP fusions increase protein antigen production, have the potential to yield effective vaccines, and also guide design of effective proteins that can be encoded by nucleic acid-based and virally vectored vaccines.

2605 related Products with: Design and assessment of TRAP-CSP fusion antigens as effective malaria vaccines.

Rhodamine B octadecyl est 17β-Acetoxy-2α-bromo-5 Rat anti-porcine type II Caspase 5 Colorimetric As Caspase 10 Substrate AEVD ASK1 (Phospho Ser83) Anti Cell Meter™ TUNEL Apopt Magnesium Assay Kit Active Caspase 3 Stainin anti Aspartate Transamina Tankyrase 1 Chemiluminesc PicoProbe™ Fructose-6-P

Related Pathways

paperclip

#31967978   // Save this To Up

Immunohistochemical analysis of cancer-associated fibroblasts and podoplanin in head and neck cancer.

To immunohistochemically evaluate the association between the presence of cancer-associated fibroblasts (CAFs) and the tumour expression of podoplanin (PDPN) in head and neck squamous cell carcinoma (HNSCC) and their association with clinicopathological variables.

2325 related Products with: Immunohistochemical analysis of cancer-associated fibroblasts and podoplanin in head and neck cancer.

Head & Neck cancer tissue Head and neck cancer tiss Head and neck squamous ca Multiple head and neck ca Head & Neck cancer test t Head and neck cancer tiss Multiple head and neck ca Head & Neck cancer tissue Cancer samples: Head and Head & Neck cancer test t Multiple Head & Neck canc Cancer Samples: Head and

Related Pathways

paperclip

#31967967   // Save this To Up

Significant cardiac disease complicating Graves' disease in previously healthy young adults.

Graves' disease is associated with tachydysrythmia, cardiac ischaemia and cardiomyopathy - all uncommon in young adults without previous cardiac disease. We present three young individuals who developed cardiac complications after periods of uncontrolled Graves' disease. Subject 1: A 34-year-old female had severe thyrotoxic symptoms for weeks. Investigations showed fT4: 98.4 (11-25 pmol/L), fT3: 46.9 (3.1-6.8 pmol/L), TSH <0.01 (0.27-4.2 mU/L) and thyrotrophin receptor antibody (TRAb): 34.8 (<0.9 U//l). She had appropriate treatment but several weeks later she became breathless despite improving thyroid function. Echocardiography showed a pericardial effusion of 2.9 cm. She responded well to steroids and NSAIDs but developed active severe Graves' orbitopathy after early total thyroidectomy. Subject 2: A 28-year-old male developed thyrotoxic symptoms (fT4: 38 pmol/L, fT3: 13.9 pmol/L, TSH <0.01 (for over 6 months) and TRAb: 9.3 U/L). One month after starting carbimazole, he developed acute heart failure (HF) due to severe dilated cardiomyopathy - EF 10-15%. He partially recovered after treatment - EF 28% and had early radioiodine treatment. Subject 3: A 42-year-old woman who had been thyrotoxic for several months (fT4: 54.3; fT3 >46.1; TSH <0.01; TRAb: 4.5) developed atrial fibrillation (AF) and heart failure. Echocardiography showed cardiomegaly - EF 29%. She maintains sinus rhythm following early total thyroidectomy (EF 50%). Significant cardiac complications may occur in previously fit young adults, who have had uncontrolled Graves' disease for weeks to months. Cardiac function recovers in the majority, but early definitive treatment should be discussed to avoid Graves' disease relapse and further cardiac decompensation.

1288 related Products with: Significant cardiac disease complicating Graves' disease in previously healthy young adults.

HIV Self Test Kit, 1Test Prostate disease spectrum Infection diseases: Heli Lung disease spectrum tis Brain disease spectrum (b Beta Amyloid (1 40) ELISA rHIV gp41, soluble Antige HBV-5 panel test, sAg sAb Ovary disease spectrum (o Multiple organ diseased t Malaria pf antigen test, Colon disease spectrum ti

Related Pathways

  •  
  • No related Items
paperclip

#31967933   // Save this To Up

Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity.

The quadrivalent HPV vaccine (4vHPV) was originally recommended as a three-dose series (0/2/6 months), though delays in completing the series frequently occur. We previously found delayed dosing in girls resulted in similar or higher antibody titers compared to on-time dosing. Archived sera from 262 healthy females aged 9-18 recruited from pediatric clinics were tested to determine if delayed dosing intervals affected antibody avidity. Avidity index (AI; ratio of IgG Ab bound in the treated and untreated sample) was determined pre- and post-dose 3 4vHPV for each participant using a modified multiplex ELISA. Data were grouped by dosing intervals: (1) on-time dose 2 and 3, (2) delayed dose 2 and on-time dose 3, (3) on-time dose 2 and delayed dose 3, (4) delayed dose 2 and 3. Overall, mean AI was highest for HPV16 and lowest for HPV6. As expected, AI did not differ between groups 1 & 3 or groups 2 & 4 pre-dose 3, however, for most types mean AI was significantly higher both pre- and post-dose 3 for groups with delayed dose 2. For all types, mean AI was higher post-dose 3 in all delayed dosing groups compared to group 1. One month post-dose 3, there was a positive but weak correlation between AIs and antibody titer for HPV 6 (ρ = 0.25, = .0001), HPV 11 (ρ = 0.14, = .0370), HPV 16 (ρ = 0.11, = .0934), and HPV 18 (ρ = 0.37, < .0001). Our findings suggest longer intervals between doses result in higher antibody avidity, providing further evidence that delayed dosing of 4vHPV does not hinder the immune response.

1795 related Products with: Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity.

Rabbit Anti-SODD Silencer Dopamine beta-Hydroxylase formin-like 1 antibody So coiled-coil domain contai fibronectin type III and MOUSE ANTI HUMAN CD15, Pr succinate-CoA ligase, ADP succinate-CoA ligase, GDP MOUSE ANTI HUMAN CD15, Pr Docking protein 3 antibod CKLF-like MARVEL transmem Yip1 domain family, membe

Related Pathways

paperclip

#31967907   // Save this To Up

Target Alpha Therapy with Thorium-227.

Targeted alpha therapy (TAT) can deliver high localized burden of radiation selectively to cancer cells as well as the tumor microenvironment, while minimizing toxicity to normal surrounding cell. Radium-223 (Ra), the first-in-class a-emitter approved for bone metastatic castration-resistant prostate cancer has shown the ability to prolong patient survival. Targeted Thorium-227 (Th) conjugates represent a new class of therapeutic radiopharmaceuticals for TAT. They are comprised of the α-emitter Th complexed to a chelator conjugated to a tumor-targeting monoclonal antibody. In this review, the authors will focus out interest on this therapeutic agent. In recent studies Th-labeled radioimmunoconjugates showed a relevant stability both in serum and vivo conditions with a significant antigen-dependent inhibition of cell growth. Unlike Ra, the parent radionuclide Th can form highly stable chelator complexes and is therefore amenable to targeted radioimmunotherapy. The authors discuss the future potential role of Th TAT in the treatment of several solid as well as hematologic malignancies.

1525 related Products with: Target Alpha Therapy with Thorium-227.

Mouse Anti-PP2A B PR55 al Rabbit (polyclonal) AntiL Mouse Anti-LAP2 alpha Tar Rat AntiKaryopherin alpha Mouse AntiT cell receptor Recombinant Rat TNF-alpha Rabbit Anti-AGPB Alpha 1 Sheep AntiEmerin Target A IL-1 alpha, murine recomb Rabbit heat shock protein Rat AntiEPCAM Target Anti Rabbit Anti-ER-alpha Poly

Related Pathways